Vol 5 (2020): Continuous Publishing
Review paper
Published online: 2020-12-28

open access

Page views 547
Article views/downloads 604
Get Citation

Connect on Social Media

Connect on Social Media

The possibilities of pharmacological intervention in myopia

Maciej Czepita1, Elena N. Iomdina2
Ophthalmol J 2020;5:150-153.


This paper presents and discusses the current possibilities of pharmacological intervention in myopia. A review of
the latest literature regarding the pharmacological treatment of myopia has been presented.

The results of experimental research on the potential use of: atropine, oxyphenonium, pirenzepine, chlorpyrifos,
apomorphine, reserpine, 6-hydroxy dopamine, dextromethorphan, MK-801, APV, bicuculline, SR95531, CACA,
TPMPA, dextrophanol, levorphanol, D- and L-naloxane, L-NAME, formoguanamine, b-xyloside, the central and
peripheral antagonist of VIP, basic fibroblast growth factor, a solution of the basic amino acid salts in the form of
succinates, in the treatment of myopia have been described. The clinical use of pirenzepine,7-methylxanthine, and
atropine has been discussed.

The obtained results of experimental and clinical studies give hope that a new effective pharmacological method of
myopia treatment can be discovered soon.

Article available in PDF format

View PDF Download PDF file


  1. Czepita D. Myopia: incidence, pathogenesis, management and new possibilities of treatment. Russ Ophthalmol J. 2014; 7(1): 96–101.
  2. Czepita M, Czepita D, Lubiński W. The Influence of Environmental Factors on the Prevalence of Myopia in Poland. J Ophthalmol. 2017; 2017: 5983406.
  3. Morgan IG, Ohno-Matsui K, Saw SM, et al. Myopia. Lancet. 2012; 379(9827): 1739–1748.
  4. Zadnik K, Mutti DO. Incidence and distribution of refractive anomalies. In: Benjamin WJ, Borish IMO. ed. Borish’s clinical refraction. Elsevier, Butterworth Heimann, St Louis 2006: 35–55.
  5. Young FA. The effect of restricted visual space on the primate eye. Am J Ophthalmol. 1961; 52: 799–806.
  6. Raviola E, Wiesel TN, Raviola E, et al. An animal model of myopia. N Engl J Med. 1985; 312(25): 1609–1615.
  7. Goss DA. Development of the ametropias. In: Benjamin WJ, Borish IM. ed. Borish’s clinical refraction. Butterworth Heimann, Elsevier, St Louis 2006: 56–92.
  8. Norton TT, Norton TT. Animal Models of Myopia: Learning How Vision Controls the Size of the Eye. ILAR J. 1999; 40(2): 59–77.
  9. Aleman A, Schaeffel F, Tepelus TC, et al. Accommodation, refractive error and eye growth in chickens. Vision Res. 1988; 28(5): 639–657.
  10. Stone RA, Laties AM, Raviola E, et al. Increase in retinal vasoactive intestinal polypeptide after eyelid fusion in primates. Proc Natl Acad Sci U S A. 1988; 85(1): 257–260.
  11. Luft WA, Ming Y, Stell WK, et al. Variable effects of previously untested muscarinic receptor antagonists on experimental myopia. Invest Ophthalmol Vis Sci. 2003; 44(3): 1330–1338.
  12. McBrien NA, Moghaddam HO, Reeder AP, et al. Atropine reduces experimental myopia and eye enlargement via a nonaccommodative mechanism. Invest Ophthalmol Vis Sci. 1993; 34(1): 205–215.
  13. Stone RA, Lin T, Laties AM, et al. Muscarinic antagonist effects on experimental chick myopia. Exp Eye Res. 1991; 52(6): 755–758.
  14. Cottriall CL, McBrien NA, Cottriall CL, et al. The M1 muscarinic antagonist pirenzepine reduces myopia and eye enlargement in the tree shrew. Invest Ophthalmol Vis Sci. 1996; 37(7): 1368–1379.
  15. Leech EM, Cottrial CL, McBrien NA. Pirenzepine prevents form deprivation myopia in a dose dependent manner. Ophthal Physiol Opt. 1995; 15(5): 351–356.
  16. Rickers M, Schaeffel F. Dose-dependent effects of intravitreal pirenzepine on deprivation myopia and lens-induced refractive errors in chickens. Exp Eye Res. 1995; 61(4): 509–516.
  17. Geller AM, Abdel-Rahman AA, Peiffer RL, et al. The organophosphate pesticide chlorpyrifos affects form deprivation myopia. Invest Ophthalmol Vis Sci. 1998; 39(7): 1290–1294.
  18. Iuvone PM, Tigges M, Stone RA, et al. Effects of apomorphine, a dopamine receptor agonist, on ocular refraction and axial elongation in a primate model of myopia. Invest Ophthalmol Vis Sci. 1991; 35(5): 1674–1677.
  19. Rohrer B, Spira AW, Stell WK. Apomorphine blocks form-deprivation myopia in chickens by a dopamine D2-receptor mechanism acting in retina or pigmented epithelium. Vis Neurosci. 1993; 10(3): 447–453.
  20. Schaeffel F, Bartmann M, Hagel G, et al. Studies on the role of the retinal dopamine/melatonin system in experimental refractive errors in chickens. Vision Res. 1995; 35(9): 1247–1264.
  21. Li XX, Schaeffel F, Kohler K, et al. Dose-dependent effects of 6-hydroxy dopamine on deprivation myopia, electroretinograms, and dopaminergic amacrine cells in chickens. Vis Neurosci. 1992; 9(5): 483–492.
  22. Schaeffel F, Hagel G, Bartmann M, et al. 6-Hydroxy dopamine does not affect lens-induced refractive errors but suppresses deprivation myopia. Vision Res. 1994; 34(2): 143–149.
  23. Weiss S, Schaeffel F. Diurnal growth rhythms in the chicken eye: relation to myopia development and retinal dopamine levels. J Comp Physiol A. 1993; 172(3): 263–270.
  24. Fisher AJ, Seltner RLP, Stell WK. Opiate and N-methyl-D-aspartate receptors in form-deprivation myopia. Visual Neurosci. 1998; 15(6): 1089–1096.
  25. Stone RA, Liu Ji, Sugimoto R, et al. GABA, experimental myopia, and ocular growth in chick. Invest Ophthalmol Vis Sci. 2003; 44(9): 3933–3946.
  26. Seltner RL, Rohrer B, Grant V, et al. Endogenous opiates in the chick retina and their role in form-deprivation myopia. Vis Neurosci. 1997; 14(5): 801–809.
  27. Fujikado T, Kawasaki Y, Fujii J, et al. The effect of nitric oxide synthase inhibitor on form-deprivation myopia. Curr Eye Res. 1997; 16(10): 992–996.
  28. Fujikado T, Tsujikawa K, Tamura M, et al. Effect of a nitric oxide synthase inhibitor on lens-induced myopia. Ophthalmic Res. 2001; 33(2): 75–79.
  29. Westbrook AM, Crewther SG, Beresford JA, et al. Formoguanamine-induced inhibition of deprivation myopia in chick is accompanied by choroidal thinning while retinal function is retained. Vision Res. 1995; 35(14): 2075–2088.
  30. Rada JA, Johnson JM, Achen VR, et al. Inhibition of scleral proteoglycan synthesis blocks deprivation-induced axial elongation in chicks. Exp Eye Res. 2002; 74(2): 205–215.
  31. Seltner RL, Stell WK. The effect of vasoactive intestinal peptide on development of form deprivation myopia in the chick: a pharmacological and immunocytochemical study. Vision Res. 1995; 35(9): 1265–1270.
  32. Roher B, Stell WK. Basic fibroblast growth factor (bFGF) and transforming growth factor (TGF-beta) act as stop and go signals to modulate postnatal ocular growth in the chick. Exp Eye Res. 1994; 58(5): 553–562.
  33. Iomdina ЕN, Tarutta ЕP, Semchishen VА, et al. [Experimental realization of minimally invasive techniques of scleral collagen cross-linking]. Vestn Oftalmol. 2016; 132(6): 49–58.
  34. Siatkowski RM, Cotter S, Miller JM, et al. US Pirenzepine Study Group. Safety and efficacy of 2% pirenzepine ophthalmic gel in children with myopia: a 1-year, multicenter, double-masked, placebo-controlled parallel study. Arch Ophthalmol. 2004; 122(11): 1667–1674.
  35. Tan DTH, Lam DS, Chua WH, et al. Asian Pirenzepine Study Group. One-year multicenter, double-masked, placebo-controlled, parallel safety and efficacy study of 2% pirenzepine ophthalmic gel in children with myopia. Ophthalmology. 2005; 112(1): 84–91.
  36. Siatkowski RM, Cotter SA, Crockett RS, et al. U.S. Pirenzepine Study Group. Two-year multicenter, randomized, double-masked, placebo-controlled, parallel safety and efficacy study of 2% pirenzepine ophthalmic gel in children with myopia. J AAPOS. 2008; 12(4): 332–339.
  37. Trier K, Munk Ribel-Madsen S, Cui D, et al. Systemic 7-methylxanthine in retarding axial eye growth and myopia progression: a 36-month pilot study. J Ocul Biol Dis Infor. 2008; 1(2-4): 85–93.
  38. Chia A, Chua WH, Cheung YB, et al. Atropine for the treatment of childhood myopia: safety and efficacy of 0.5%, 0.1%, and 0.01% doses (Atropine for the Treatment of Myopia 2). Ophthalmology. 2012; 119(2): 347–354.
  39. Azuara-Blanco A, Logan N, Strang N, et al. Low-dose (0.01%) atropine eye-drops to reduce progression of myopia in children: a multicentre placebo-controlled randomised trial in the UK (CHAMP-UK)-study protocol. Br J Ophthalmol. 2020; 104(7): 950–955.
  40. Cheng J, Yang Y, Kong X, et al. The Effect of 0.01% Atropine Eye Drops on the Ocular Surface in Children for the Control of Myopia-The Primary Results from a Six-Month Prospective Study. Ther Clin Risk Manag. 2020; 16: 735–740.
  41. Guo L, Fan L, Tao J, et al. Use of Topical 0.01% Atropine for Controlling Near Work-Induced Transient Myopia: A Randomized, Double-Masked, Placebo-Controlled Study. J Ocul Pharmacol Ther. 2020; 36(2): 97–101.
  42. Li FF, Kam KaW, Zhang Y, et al. Differential Effects on Ocular Biometrics by 0.05%, 0.025%, and 0.01% Atropine: Low-Concentration Atropine for Myopia Progression Study. Ophthalmology. 2020; 127(12): 1603–1611.
  43. Fu A, Stapleton F, Wei Li, et al. Effect of low-dose atropine on myopia progression, pupil diameter and accommodative amplitude: low-dose atropine and myopia progression. Br J Ophthalmol. 2020; 104(11): 1535–1541.
  44. Yam JC, Li FF, Zhang X, et al. Two-Year Clinical Trial of the Low-Concentration Atropine for Myopia Progression (LAMP) Study: Phase 2 Report. Ophthalmology. 2020; 127(7): 910–919.
  45. Grzybowski A, Armesto A, Szwajkowska M, et al. The Role of Atropine Eye Drops in Myopia Control. Curr Pharm Des. 2015; 21(32): 4718–4730.
  46. Grzybowski A, Sobolewska B. Dobrowolsky from St. Petersburg and Hosch from Basel reported improvement of myopia after atropine use in 1868 and 1871. Strabismus. 2018; 26(1): 46.